Bank of America Raises Agilent Technologies (NYSE:A) Price Target to $140.00

Agilent Technologies (NYSE:A) had its target price boosted by equities researchers at Bank of America from $134.00 to $140.00 in a note issued to investors on Tuesday, MarketBeat reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. Bank of America‘s target price suggests a potential upside of 5.23% from the company’s current price.

Several other analysts have also weighed in on the company. Robert W. Baird decreased their price objective on Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating on the stock in a report on Thursday, May 30th. Oppenheimer raised their target price on Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. TD Cowen cut their target price on Agilent Technologies from $163.00 to $153.00 and set a “buy” rating for the company in a research report on Thursday, May 30th. Stifel Nicolaus cut their target price on Agilent Technologies from $163.00 to $151.00 and set a “buy” rating for the company in a research report on Thursday, May 30th. Finally, Citigroup cut their target price on Agilent Technologies from $145.00 to $135.00 and set a “neutral” rating for the company in a research report on Thursday, May 30th. One analyst has rated the stock with a sell rating, six have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $136.88.

Agilent Technologies Price Performance

Shares of NYSE:A opened at $133.04 on Tuesday. Agilent Technologies has a 1-year low of $96.80 and a 1-year high of $155.35. The firm has a market capitalization of $38.82 billion, a PE ratio of 31.45, a PEG ratio of 4.57 and a beta of 1.07. The business’s 50 day moving average is $139.69 and its 200-day moving average is $138.49. The company has a current ratio of 2.15, a quick ratio of 1.64 and a debt-to-equity ratio of 0.34.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Wednesday, May 29th. The medical research company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.03. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The company had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.58 billion. During the same quarter last year, the firm earned $1.27 EPS. Agilent Technologies’s revenue for the quarter was down 8.4% compared to the same quarter last year. Sell-side analysts predict that Agilent Technologies will post 5.25 earnings per share for the current year.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the transaction, the chief executive officer now directly owns 25,185 shares of the company’s stock, valued at $3,274,050. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Agilent Technologies news, SVP Dominique Grau sold 15,000 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the completion of the transaction, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at $6,595,494.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the transaction, the chief executive officer now directly owns 25,185 shares of the company’s stock, valued at $3,274,050. The disclosure for this sale can be found here.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in A. FMR LLC lifted its holdings in shares of Agilent Technologies by 32.8% in the third quarter. FMR LLC now owns 963,126 shares of the medical research company’s stock valued at $107,697,000 after purchasing an additional 237,870 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Agilent Technologies by 0.9% during the third quarter. Acadian Asset Management LLC now owns 14,437 shares of the medical research company’s stock worth $1,612,000 after acquiring an additional 124 shares in the last quarter. LPL Financial LLC raised its holdings in Agilent Technologies by 11.5% during the third quarter. LPL Financial LLC now owns 57,954 shares of the medical research company’s stock worth $6,480,000 after acquiring an additional 5,978 shares in the last quarter. Stifel Financial Corp raised its holdings in Agilent Technologies by 259.9% during the third quarter. Stifel Financial Corp now owns 119,582 shares of the medical research company’s stock worth $13,375,000 after acquiring an additional 86,355 shares in the last quarter. Finally, Natixis Advisors L.P. raised its holdings in Agilent Technologies by 20.9% during the third quarter. Natixis Advisors L.P. now owns 64,155 shares of the medical research company’s stock worth $7,174,000 after acquiring an additional 11,075 shares in the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.